Comparative study of the immunogenicity in mice and monkeys of an inactivated CA16 vaccine made from a human diploid cell line

References

• Huang XY, Kang K, Xu YL, Wei HY, Li XL, Ma H, You AG, Chen HM, Xu BL. [Etiology surveillance of hand-foot-mouth disease in Henan province between 2008 and 2011]. Zhonghua Yu Fang Yi Xue Za Zhi 2012; 46:883 - 7; PMID: 23363860
   PubMedGoogle Scholar
• Lü H-k. ZHANG Y-j, MIU Z-p, CAI J, QIN S-w, GONG L-m, CHEN Z-p. Epidemiological and pathogenic characteristics of hand,foot,and mouth disease in Zhejiang province, 2008-2009. Chin J Publ Health 2012; 28:105 - 7
   Google Scholar
• Rabenau HF, Richter M, Doerr HW. Hand, foot and mouth disease: seroprevalence of Coxsackie A16 and Enterovirus 71 in Germany. Med Microbiol Immunol 2010; 199:45 - 51; http://dx.doi.org/10.1007/s00430-009-0133-6; PMID: 19941005
   PubMed Web of Science ®Google Scholar
• Ishimaru Y, Nakano S, Yamaoka K, Takami S. Outbreaks of hand, foot, and mouth disease by enterovirus 71. High incidence of complication disorders of central nervous system. Arch Dis Child 1980; 55:583 - 8; http://dx.doi.org/10.1136/adc.55.8.583; PMID: 6254449
   PubMed Web of Science ®Google Scholar
• Jia L, Zhao CS, Zhang L, Li S, Zhang DT, Liu BW, Wang QY, Li XY. [Comparisons of epidemiological and clinical characteristics in children with hand-foot-mouth disease caused by Enterovirus 71 and Coxackievirus A16]. Zhongguo Dang Dai Er Ke Za Zhi 2011; 13:635 - 7; PMID: 21849112
   PubMedGoogle Scholar
• Xu W, Liu CF, Yan L, Li JJ, Wang LJ, Qi Y, Cheng RB, Xiong XY. Distribution of enteroviruses in hospitalized children with hand, foot and mouth disease and relationship between pathogens and nervous system complications. Virol J 2012; 9:8; http://dx.doi.org/10.1186/1743-422X-9-8; PMID: 22230340
   PubMed Web of Science ®Google Scholar
• Wright HT Jr., Landing BH, Lennette EH, McALLISTER RM. Fatal infection in an infant associated with Coxsackie virus group A, type 16. N Engl J Med 1963; 268:1041 - 4; http://dx.doi.org/10.1056/NEJM196305092681904; PMID: 14001956
   PubMed Web of Science ®Google Scholar
• Yi D, Sun L, Chen Q, Zhang N, Han J, Ye X, Su X. [Comparison of three detection methods for neutralizing antibodies induced by Coxsackievirus A16 vaccine]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 2013; 29:287 - 91; PMID: 23643087
   PubMedGoogle Scholar
• Yang E, Zhao H, Zhang Y, Liu J, Liao Y, Wang L, Cui P, Yang L, Liu L, Dong C, et al. A comparative study of the characteristics of two Coxsackie A virus type 16 strains (genotype B). Sci China Life Sci 2012; 55:336 - 42; http://dx.doi.org/10.1007/s11427-012-4313-z; PMID: 22566090
   PubMed Web of Science ®Google Scholar
• Zhao H, Li HY, Han JF, Deng YQ, Li YX, Zhu SY, He YL, Qin ED, Chen R, Qin CF. Virus-like particles produced in Saccharomyces cerevisiae elicit protective immunity against Coxsackievirus A16 in mice. Appl Microbiol Biotechnol 2013; 97:10445 - 52; http://dx.doi.org/10.1007/s00253-013-5257-3; PMID: 24085395
   PubMed Web of Science ®Google Scholar
• Liu Q, Yan K, Feng Y, Huang X, Ku Z, Cai Y, Liu F, Shi J, Huang Z. A virus-like particle vaccine for coxsackievirus A16 potently elicits neutralizing antibodies that protect mice against lethal challenge. Vaccine 2012; 30:6642 - 8; http://dx.doi.org/10.1016/j.vaccine.2012.08.071; PMID: 22959985
   PubMed Web of Science ®Google Scholar
• Cai Y, Liu Q, Huang X, Li D, Ku Z, Zhang Y, Huang Z. Active immunization with a Coxsackievirus A16 experimental inactivated vaccine induces neutralizing antibodies and protects mice against lethal infection. Vaccine 2013; 31:2215 - 21; http://dx.doi.org/10.1016/j.vaccine.2013.03.007; PMID: 23499596
   PubMed Web of Science ®Google Scholar
• Mao Q, Wang Y, Gao R, Shao J, Yao X, Lang S, Wang C, Mao P, Liang Z, Wang J. A neonatal mouse model of coxsackievirus A16 for vaccine evaluation. J Virol 2012; 86:11967 - 76; http://dx.doi.org/10.1128/JVI.00902-12; PMID: 22951825
   PubMed Web of Science ®Google Scholar
• Zheng-ling L. LiHua L, Run-xiang Y. Research and preliminary application of Cox A16 antigen detection Kit. Chinese Journal of Health Laboratory Technology 2013; 4:801 - 5
   Google Scholar
• Raczniak GA, Bulkow LR, Bruce MG, Zanis CL, Baum RL, Snowball MM, Byrd KK, Sharapov UM, Hennessy TW, McMahon BJ. Long-term immunogenicity of hepatitis A virus vaccine in Alaska 17 years after initial childhood series. J Infect Dis 2013; 207:493 - 6; http://dx.doi.org/10.1093/infdis/jis710; PMID: 23204169
   PubMed Web of Science ®Google Scholar
• Dong C, Wang J, Liu L, Zhao H, Shi H, Zhang Y, Jiang L, Li Q. Optimized development of a candidate strain of inactivated EV71 vaccine and analysis of its immunogenicity in rhesus monkeys. Hum Vaccin 2010; 6:1028 - 37; http://dx.doi.org/10.4161/hv.6.12.12982; PMID: 21150270
   PubMed Web of Science ®Google Scholar
• Mao Q, Wang Y, Gao R, Shao J, Yao X, Lang S, Wang C, Mao P, Liang Z, Wang J. A neonatal mouse model of coxsackievirus A16 for vaccine evaluation. J Virol 2012; 86:11967 - 76; http://dx.doi.org/10.1128/JVI.00902-12; PMID: 22951825
   PubMed Web of Science ®Google Scholar
• Yu CK, Chen CC, Chen CL, Wang JR, Liu CC, Yan JJ, Su IJ. Neutralizing antibody provided protection against enterovirus type 71 lethal challenge in neonatal mice. J Biomed Sci 2000; 7:523 - 8; http://dx.doi.org/10.1007/BF02253368; PMID: 11060501
   PubMed Web of Science ®Google Scholar
• Liu L, Zhang Y, Wang J, Zhao H, Jiang L, Che Y, Shi H, Li R, Mo Z, Huang T, et al. Study of the integrated immune response induced by an inactivated EV71 vaccine. PLoS One 2013; 8:e54451; http://dx.doi.org/10.1371/journal.pone.0054451; PMID: 23372725
   PubMed Web of Science ®Google Scholar
• Teng Z, Tan XJ, Shao JJ, Zhang Y, Kuang XZ, Zhang X, Xu WB. [Epidemiology and etiology of hand-foot-and-mouth disease in Shanghai, 2009]. Bing Du Xue Bao 2010; 26:437 - 42; PMID: 21344746
   PubMedGoogle Scholar
• Chatproedprai S, Theanboonlers A, Korkong S, Thongmee C, Wananukul S, Poovorawan Y. Clinical and molecular characterization of hand-foot-and-mouth disease in Thailand, 2008-2009. Jpn J Infect Dis 2010; 63:229 - 33; PMID: 20657060
   PubMed Web of Science ®Google Scholar
• Mao Q, Wang Y, Yao X, Bian L, Wu X, Xu M, Liang Z. Coxsackievirus A16: Epidemiology, diagnosis, and vaccine. Hum Vaccin Immunother 2013; 10; Forthcoming PMID: 24231751
   PubMed Web of Science ®Google Scholar
• Ni H, Yi B, Yin J, Fang T, He T, Du Y, Wang J, Zhang H, Xie L, Ding Y, et al. Epidemiological and etiological characteristics of hand, foot, and mouth disease in Ningbo, China, 2008-2011. J Clin Virol 2012; 54:342 - 8; http://dx.doi.org/10.1016/j.jcv.2012.04.021; PMID: 22652041
   PubMed Web of Science ®Google Scholar
• Guo R, Cao YY, Dai ZZ, Qu SR, Zhuang JY. [Characteristics of a human diploid cell line, KMB-17]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 1981; 3:226 - 30; PMID: 6459859
   PubMedGoogle Scholar
• Ortega A, Amorós D, García de la Torre J. Global fit and structure optimization of flexible and rigid macromolecules and nanoparticles from analytical ultracentrifugation and other dilute solution properties. Methods 2011; 54:115 - 23; http://dx.doi.org/10.1016/j.ymeth.2010.12.004; PMID: 21163355
   PubMed Web of Science ®Google Scholar
• Koticha DK, Barbagallo CA, Rapiejko PJ. Rapid, Ultrafiltration-based Method for Purification of Monoclonal Antibodies from Hybridoma Supernatants. 2008 [2013-10-10].
   Google Scholar
• Hochstrasser DF, Patchornik A, Merril CR. Development of polyacrylamide gels that improve the separation of proteins and their detection by silver staining. Anal Biochem 1988; 173:412 - 23; http://dx.doi.org/10.1016/0003-2697(88)90208-4; PMID: 3189819
   PubMed Web of Science ®Google Scholar
• Bey E, Golombick T. A comparison of three methods for titration of poliovirus vaccines. J Virol Methods 1984; 9:123 - 30; http://dx.doi.org/10.1016/0166-0934(84)90004-1; PMID: 6096387
   PubMed Web of Science ®Google Scholar
• Streeck H, Frahm N, Walker BD. The role of IFN-gamma Elispot assay in HIV vaccine research. Nat Protoc 2009; 4:461 - 9; http://dx.doi.org/10.1038/nprot.2009.7; PMID: 19282851
   PubMed Web of Science ®Google Scholar